Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

X experienced improvements in disease activity as measured by DAS28. Seventy-six percent of patients in the combined golimumab group were classified as DAS28 (CRP) responders, and 38 percent achieved DAS 28 remission, compared with 61 percent and 28 percent of patients receiving placebo and MTX, respectively (p<0.001 for responders and p=0.031 for remission).

"We are encouraged by the findings of both of these Phase 3 studies," said Robert J. Spiegel, M.D., chief medical officer, Schering-Plough Research Institute. "Golimumab holds great promise as an anti-TNF therapy for patients who may benefit from monthly subcutaneous injections for RA and related rheumatic diseases."

In March 2008, Centocor Inc. and Schering-Plough Corporation (NYSE: SGP) announced that a Marketing Authorization Application (MAA) had been submitted to the European Medicines Agency requesting the approval of golimumab as a monthly subcutaneous treatment for adults with RA, psoriatic arthritis and ankylosing spondylitis. The initial submission and Phase 3 development programs are unprecedented among anti-TNF-alpha therapies, as they mark the first time that an MAA has been proposed for review inclusive of three unique disease states. Golimumab, Centocor's and Schering-Plough's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy.

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite MTX therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus MTX, golimumab 100 mg plus placebo or placebo plus MTX at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Golimum
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Releases of the ... Aedes aegypti , , reduced the dengue mosquito ... by 95%, well below the modelled threshold ... , The journal PLOS Neglected Tropical Diseases ... genetically engineered mosquitoes. The results showed that in Juazeiro ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today announced ... Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM),System in ... Diabetes. Echo,s non-invasive,Symphony tCGM System consists of ... the Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, today announced that it will host a ... 2008, at 9:00 am Eastern Time (3:00 pm,Central ... financial,results. Micromet anticipates releasing its financial results at ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... ... the recent report by JAMA Internal Medicine published on June 22, 2015, ... declared a war on obesity in the United States. , "Obesity is one of ... magnitude of this discovery. For that reason, I am declaring, along with my Health ...
(Date:7/2/2015)... ... 02, 2015 , ... When Walker Parking Consultants specified Kenall ... Minnesota, they knew it would save the university energy and maintenance costs. What ... total energy savings after installation was an impressive 89 percent, which resulted in ...
(Date:7/2/2015)... ... ... full swing, Americans are flocking to Canada’s many lakes to reel in their fair share ... and it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to ... a huge industry, and Americans make up the vast majority of anglers from outside of ...
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... increased over the past years with more than one-third ... alternative medicine. Alternative or complementary therapies include treatments such ... vitamins. ,Researchers in Boston compared the results ... National Health Interview Survey taken in 2002. Results showed ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... children who have Duchenne muscular dystrophy (DMD) with the oral ... despite the side effects of the drug . Most patients ... teens or early 20s from respiratory failure or heart problems. ... questioned whether its side effects, which can range from weight ...
... carry a gene that produces a higher level of ... for stroke.// ,Researchers reviewed medical literature on homocysteine ... study results were observational in nature. A standard scientific ... looking at data on the link between homocysteine and ...
... disease who follow a heart-healthy diet and weight-loss regimen ... that raise HDL (high-density lipoproteins or "good" cholesterol) levels, ... patients younger than 76 with low HDL and known ... a heart-healthy diet and lost weight. However, results showed ...
Cached Medicine News:
... Measles IgG Enzymelinked Immunosorbent Assays(ELISA) is intended ... IgG antibody to Measles Rubeola) virus in ... used for the determination of immune status. ... to demonstrate seroconversion or a significant rise ...
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
The DSL-05-10-MEG Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Measles Virus in human serum. This assay is intended fo...
... is a glucocorticoid produced by the adrenal ... It is secreted with a circadian periodicity, ... the morning. Cortisol is often elevated in ... stress, AIDS, and in the visceral fat ...
Medicine Products: